Calculating the number needed to treat for trials where the outcome is time to an event

British Medical Journal

Volumn 319, Issue 7223, 1999, Pages 1492-1495

  Altman, Douglas G ^a   Andersen, Per Kragh ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; CLINICAL TRIAL; DATA ANALYSIS; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PROBABILITY; SAMPLE; SURVIVAL; TREATMENT OUTCOME;

EID: 0033524123     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.319.7223.1492     Document Type: Article

References (11)

1. 1 Cook RJ, Sackett DI.. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
2. 2 Sackett DL, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine. How to practice and teach EBM. London: Churchill Livingstone, 1997:136-11, 168-70.
3. 3 Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology: a basic science for clinical medicine, 2nd ed. Boston: Litlle Brown, 1991:208.
4. 4 Altman DG, De Stavola BL, Love SR, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72:511-8.
5. 5 Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 1996;348:1605-10.
6. 6 McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-20.
7. 7 Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
8. 8 Malmberg K for the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study Group, Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997;314:1512-5.
9. 9 Lad T, Rubinstein L, Sadeghi A. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. J Clin Oncol 1988;6:9-17.
10. 10 Piantadosi S. Clinical trials. A methodologic approach. Chichester: John Wiley, 1997.
11. 11 Miller DB. Secondary prevention for ischemic heart disease. Relative numbers needed to treat with different therapies. Arch Intern Med 1997;157:2045-52.